Viatris Acknowledges Potential For US Symbicort Opportunity In 2022
US-Based Firm Watches On ‘As Court Proceedings Develop’
Following its recent landmark approval for the first US generic version of AstraZeneca’s Symbicort blockbuster, Viatris has commented on the potential to move on a pre-patent expiry launch, amid a recent favorable court decision.
